Merck KGaA To Divest its Allergy Business Allergopharma to DermapharmBy
Merck KGaA has agreed to sell its allergy business, Allergopharma, to Dermapharm Holding, a manufacturer of off-patent branded medicines for selected markets in Germany, for an undisclosed purchase price.
The transaction encompasses the Allergopharma business in Europe and Asia, including the therapeutic and diagnostic product portfolio as well as a production site in Reinbek near Hamburg, Germany. Allergopharma’s adrenaline autoinjector development project for the treatment of anaphylactic reactions is not part of the transaction and will remain with Merck KGaA.
Allergopharma focuses on allergen-specific immunotherapies of Type 1 allergies such as hay fever or allergic asthma. Allergopharma products are available in 18 countries worldwide. In 2018, Allergopharma generated sales of EUR 88 million ($95 million). The transaction is expected to close by the end of the second quarter of 2020.
Dermapharm is a manufacturer of off-patent branded medicines for selected markets in Germany and is headquartered in Grünwald near Munich, Germany. Its main production site is in Brehna near Leipzig. Dermapharm has more than 900 marketing authorizations for approximately 250 active ingredients that are commercialized either as medicines, food supplements or supplemental balanced diets.
Source: Merck KGaA